Clinical trial · Interventional
Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors
NCT00116896CI-TRIAL-00001910completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| OSI-7904L | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Advanced and/or metastatic solid tumor for which no effective therapy is available * ECOG performance status 0-2 * Adequate bone marrow, hepatic and renal function Exclusion Criteria: * Patients with active or uncontrolled infections * Neurotoxicity \>= Grade 2 * Symptomatic brain metastases which are not stable
References
Publications (0)
Data not yet available
No reference posted for this study.